Clinical Trials
38 trialsNCT01804686 2026-06-05
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05424822 2026-06-05
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05963074 2026-06-05
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06299540 2026-06-05
QOLIBRI
Janssen Cilag S.A.S.
Recruiting
NCT06788509 2026-06-05
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT07602088 2026-06-05
REALITY-RO
Janssen Research & Development, LLC
Recruiting
NCT03960840 2026-06-04
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
NCT04502030 2026-06-04
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Octapharma
Phase 3 Completed
NCT06943872 2026-06-04
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT05006716 2026-06-03
CaDAnCe-101
BeOne Medicines
Phase 1/2 Recruiting
NCT05091424 2026-06-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 1 Recruiting
NCT06973187 2026-06-03
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3 Recruiting
NCT07139873 2026-06-03
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT07277231 2026-06-03
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
NCT03625037 2026-06-02
EPCOREâ„¢ NHL-1
Genmab
Phase 1/2 Active not recruiting
NCT04542824 2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04623541 2026-06-02
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT05753501 2026-06-02
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Phase 1 Active not recruiting
NCT06539182 2026-06-02
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Dizal Pharmaceuticals
Phase 2 Recruiting
NCT06073821 2026-06-01
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
NCT05458297 2026-05-29
MK-2140-006
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT05515406 2026-05-29
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
Ono Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT06637501 2026-05-29
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2 Active not recruiting
NCT06846671 2026-05-29
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
NCT05437250 2026-05-28
NAOS
AstraZeneca
Active not recruiting
NCT06136559 2026-05-28
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06528301 2026-05-28
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
Phase 1 Recruiting
NCT07221500 2026-05-28
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
Phase 2 Recruiting
NCT02477696 2026-05-27
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting
NCT07205315 2026-05-27
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting
NCT07609823 2026-05-27
A Phase 2 Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2 Not yet recruiting
NCT07609862 2026-05-27
A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2 Not yet recruiting
NCT07218341 2026-05-22
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 4 Recruiting
NCT07271667 2026-05-22
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc.
Phase 2 Recruiting
NCT05057494 2026-05-19
MAJIC
AstraZeneca
Phase 3 Active not recruiting
NCT06548152 2026-05-19
AQUALIS
AstraZeneca
Recruiting
NCT06588478 2026-05-19
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 2 Recruiting
NCT05947851 2026-05-18
BELLWAVE-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting